

Information on the total number of voting rights and shares

Gosselies, Belgium, 21 June 2019, 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces an increase in the total number of voting rights and shares as a result of the issuance of new shares on 19 June 2019 following the conversion of convertible bonds issued on the private placement on 7 March 2018. The following information is published in accordance with Article 15 of the Belgian Law of 2 May 2007 on the publication of major shareholdings in issuers whose shares are admitted to trading on regulated market.

Total amount of share capital on 8 May 2019	EUR 13,285,493
Total number of shares with voting rights on 8 May 2019	8,809,871
Total number of new shares issued on 19 June 2019	142,100

Total amount of share capital on 19 June 2019	EUR 13,500,064
Total number of shares with voting rights on 19 June 2019	8,951,971 (a)
Total number of voting rights (denominator) on 19 June 2019	8,951,971
Total number of attributed warrants	210,498
Total number of convertible bonds outstanding	282
Total number of bond warrants outstanding	1,180
Total number of shares with voting rights following the exercise of the bond warrants, the conversion of the convertible bonds and the attributed warrants ⁽¹⁾	1,113,212 (b)
Total number of diluted shares	10,065,183 (a+b)

⁽¹⁾ Based on the conversion price of EUR 4.0489 (92% of the Volume-Weighted-Averaged-Price of Bone Therapeutics on 19 June 2019)

